Aegis Therapeutics has received a US patent covering Parathyroid Hormone (PTH) and PTH analogue compositions suitable for metered nasal spray, oral, and injectable delivery.

The stabilized PTH formulations incorporate Aegis' Intravail/ProTek excipients suitable for all routes of administration.

Intravail and ProTek excipients allow for non-invasive delivery with high efficiency and stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics.

The excipients also avoid the oxidative damage caused by polysorbate surfactants presently used in many protein injectable drugs.

The company has also announced that that formulations of teriparatide based upon Intravail/ProTe show nasal bioavailability offering the prospect of a non-injectable PTH drug.

Non-injectable dosage forms of previously injectable-only drugs provide patient convenience and acceptance, better compliance and avoidance of needle-stick injury.